The Quantellect read.As of Nov 19, 2026, 3 active firms cover ADMA Biologics Inc: 2 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $17.00 to $18.00, so the covering firms are broadly aligned. The average target of $17.50 sits 29% above the current $13.57. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near 12% this year and 27% next, consensus EPS building from about $0.19 next quarter toward $0.94 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Buy
Strong Buy00%
Buy267%
Neutral133%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$17.50
+29.0% upside
Average target across 2 active firms as of Nov 19, 2026 vs $13.57 current
Highest Target$18.00
Average Target$17.50
Lowest Target$17.00
Detailed analyst forecasts for ADMA
Showing 1–3 of 3 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 2 of 3 active firms rate ADMA a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ADMA EPS & revenue forecast
EPS · NEXT QUARTER
$0.19
Range $0.16 – $0.22 · 2 analysts · +12% YoY
Next period, 2 analysts expect ADMA Biologics Inc to earn $0.19 a share (range $0.16 – $0.22), versus $0.17 a year earlier. Full-year consensus is $0.81, growing to $0.94 the year after.
REVENUE · NEXT QUARTER
$134.1M
Range $121.1M – $141.5M · 2 analysts · +9% YoY
Revenue is expected to reach $134.1M (range $121.1M – $141.5M), +9.0% year-over-year. Full-year consensus is $534.8M, rising to $612.6M next year.
Top analysts covering ADMA Biologics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ADMA.
#1
Anthony Petrone
Mizuho · Rank #121
Buy
$17.00+25.3% to target
Overall win rate
45%
+ Follow
#2
Kristen Kluska
Cantor Fitzgerald · Rank #232
Neutral
No targeton ADMA
Overall win rate
38%
+ Follow
#3
Elliot Wilbur
Raymond James · Rank #364
Buy
$32.00+135.8% to target
Overall win rate
32%
+ Follow
#4
GN
Gary Nachman
Canaccord Genuity
Buy
$18.00+32.6% to target
Coverage
—
+ Follow
#5
Ryan Deschner
Raymond James
Buy
$21.00+54.8% to target
Coverage
—
+ Follow
ADMA stock forecast FAQ
What is ADMA's average 12-month price target?+
The 2 active firms with a live target average $17.50 for ADMA Biologics Inc over the next 12 months, ranging from a $18.00 high to a $17.00 low, as of Nov 19, 2026.
Is ADMA stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 3 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ADMA?+
The Street-high target is $18.00 (Canaccord Genuity), and the Street-low is $17.00 (Mizuho). The average of all 2 active-firm targets is $17.50.
How many active Wall Street firms cover ADMA?+
3 active firms have a recognized rating on ADMA Biologics Inc as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ADMA?+
Among analysts who currently cover ADMA, Anthony Petrone of Mizuho has the strongest overall Quantellect track record (Rank #121). Their current call is Buy with a $17.00 target.
What is ADMA Biologics Inc's projected EPS for next quarter?+
The consensus estimate is $0.19 per share (range $0.16 – $0.22) across 2 analysts. Full-year EPS is projected at $0.81, rising to $0.94 the following year.
How much revenue is ADMA Biologics Inc expected to report next quarter?+
Consensus revenue is $134.1M (range $121.1M – $141.5M). Full-year revenue is projected at $534.8M, growing to $612.6M next year.
Have analysts been upgrading or downgrading ADMA lately?+
As of Nov 19, 2026, 2 of 3 active firms rate ADMA a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ADMA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.